Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

This study is currently recruiting participants.

This is a Phase 1 clinical trial, a type of research study. The purpose of this phase 1 clinical trial is to find out whether a new study drug, ibrutinib, is safe in patients with T-cell non-Hodgkin lymphoma that has either come back or not responded to treatment. In this phase 1 study, different doses of ibrutinib (560 mg and 840 mg daily) will be tested to see what effect the drug has on the patient and the disease.

Study Type:  Interventional

Study Design:  

Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title:  A Multicenter Phase I Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

Conditions:  

T-cell Lymphoma
Relapsed and Refractory T-cell Lymphoma

Interventions:  Drug: Ibrutinib

Phase:  Phase 1

External Link:  https://clinicaltrials.gov/ct2/show/NCT02309580